A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
Active, not recruiting · Phase 1, Phase 2 · NCT05828511
Conditions: Multiple Myeloma
At a glance
- Research payments reported, 2025
- $2.7M
- U.S. investigators named
- 12
- Sites paid
- 12
- Planned or actual enrollment
- 148
About the trial
- Sponsor
- Regeneron Pharmaceuticals
- Tested
- Linvoseltamab (drug)
- Dates
- Started 2023-12-19; completion 2035-11-02
- Results posted
- Not yet
This study is researching an experimental drug called linvoseltamab (called "study drug"). The study is focused on participants with newly diagnosed multiple myeloma (NDMM) who are eligible for high dose chemotherapy with autologous stem cell transplantation (transplant-eligible) or ineligible for autologous stem cell transplantation (transplant-ineligible). The aim of this clinical trial is to study the safety, tolerability (how the body reacts to the drug), and effectiveness (tumor shrinkage) of linvoseltamab in study participants with NDMM as a first step in determining if the study drug has a role in the treatment of NDMM. This study consists of 2 phases: * In Phase 1 Parts A and B, t…
From ClinicalTrials.gov, last updated 2026-11-06. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Regeneron Pharmaceuticals, Inc. reported $2.7M in research payments for this study in 2025 (1,034 payments).
Products named: Lynozyfic
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Sarah M. Larson, M.D. Hematology & Oncology · Los Angeles, CA
- Lisa X. Lee, M.D. Hematology & Oncology · Irvine, CA
- Henning H. Schade, M.D. Hematology & Oncology · Denver, CO
- Don A. Stevens, M.D. Medical Oncology · Louisville, KY
- Jeffrey A. Zonder, MD Hematology & Oncology · Detroit, MI
- Christopher J. Ferreri, MD Internal Medicine · Charlotte, NC
- Mansi R. Shah, M.D. Hematology · New Brunswick, NJ
- Rajshekhar Chakraborty, MD Medical Oncology · New York, NY
- Gareth Morgan, MD Hematology & Oncology · New York, NY
- Michael W. Schuster, MD Hematology & Oncology · New York, NY
- Yubin Kang, M.D. Hematology · Oklahoma City, OK
- Robert Z. Orlowski, MD Hematology & Oncology · Houston, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Ut MD Anderson Cancer Center $593,546
- Rutgers the State University $424,646
- Norton Healthcare Inc $308,338
- Sarah Cannon Research Institute LLC $244,287
- Carolinas Medical Center-Northeast, NC $230,763
- Uci Health - Fountain Valley, CA $226,368
- Ronald Reagan UCLA Medical Center, CA $215,203
- New York University $142,938
- Research Foundation of State University of New York $128,661
- Trustees of Columbia University $119,519
- Karmanos Cancer Center, MI $53,174
- Duke University $34,141
- $16,504
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.